Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function;Gemcitabine/carboplatin-chemotherapie in der behandlung des metastasierten urothelkarzinoms unter besonderer berücksichtigung von patienten mit eingeschränkter nierenfunktion

Aktuelle Urologie

Volumn 37, Issue 5, 2006, Pages 363-368

  Helke, Christian ^a,b   May, M ^a   Hoschke, B ^a  

^a Department of Surgery   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Carboplatin; Gemcitabine; Impaired renal function; TCC

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

AGED; ARTICLE; BLADDER; BLADDER TUMOR; CANCER INVASION; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION TEST; KIDNEY PELVIS; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; URETER; URETER TUMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY PELVIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SURVIVAL RATE; URETER; URETERAL NEOPLASMS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 33750571118     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-932157     Document Type: Article

References (25)

1. Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA, Hellenic Cooperative Oncology Group. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004 Jan 15; 22 (2): 220-228
2. Bellmunt J, deWit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 2001 Nov; 37 (17): 2212-2215
3. Carles J, Nogue M. Gemcitabine/carboplatin in advanced urothelial cancer. Semin Oncol 2001 Jun; 28 (3 Suppl 10): 19-24
4. Chatelut E, Pivot X, Otto J, Chevreau C, Thyss A, Renee N, Milano G, Canal P. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 2000 Jan; 36 (2): 264-269
5. Gandara DR, Lau DH, Lara Jr PN, Edelman MJ. Gemcitabine/carboplatin combination regimens: importance of dose schedule. Oncology (Williston Park) 2000 Jul; 14 (7 Suppl 4): 26-30
6. Hoschke B, May M, Seehafer M, Helke C. Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium. Int J Urol 2004 Jul; 11 (7): 461-466
7. Johannsen M, Sachs M, Roigas J, Hinke A, Staack A, Loening SA, Schnorr D, Wille AH. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. Eur Urol 2005 Aug; 48 (2): 246-251
8. Linardou H, Aravantinos G, Efstathious E, Kalofonos C, Anagnostopoulus A, Deliviotis C, Bafaloukos D, Dimopoulos MA, Bamias A. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy wit advanced bladder carcinoma: phase II study of the Hellenic cooperative oncology group. Urology 2004; 64 (3): 479-484
9. Lipp HP, Bokemeyer C. Individuelle Carboplatindosierung. Anpassung an die Nierenfunktion. Arzneimitteltherapie 1997; 2: 42-48
10. Loehrer Sr PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992 Jul; 10 (7): 1066-1073
11. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M, De Lena M. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998 Jul; 34 (8): 1208-1212
12. Meluch AA, Greco FA, Burris 3rd HA, O'Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworfh JD. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001 Jun 15; 19 (12): 3018-3024
13. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997 Dec; 15 (12): 3441-3445
14. Nogue-Aliguer M, Carles J, Arrivi A, Juan O, Alonso L, Font A, Mellado B, Garrido P, Saenz A Spanish Cooperative Group. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003 May 1; 97 (9): 2180-2186
15. Petrioli R, Frediani B, Manganelli A, Barbanti G, De Capua B, De Lauretis A, Salvestrini F, Mondillo S, Francini G. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996 Jan 15; 77 (2): 344-351
16. Raabe NK, Fossa SD, Para G. Phase II study of carboplatin in locally advanced and metastatic trasitional cell carcinoma of the urinary bladder. Br J Urol 1989; 64: 604-607
17. Redman BG, Smith DC, Flaherty L, Du W, Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. Journal of Clinical Oncology 1998; Vol 16: 1844-1848
18. Saxmann SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer Sr PJ, Trump D. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997 Jul; 15 (7): 2564-2569
19. Shannon C, Crombie C, Brooks A, Lau H, Drummond M, Gurney H. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol 2001 Jul; 12 (7): 947-952
20. Small EJ, Lew D, Redman BG, Petryfak DP, Hammond N, Gross HM, Eastham JA, Crawford ED. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 2000 Jul; 18 (13): 2537-2544
21. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997 Nov; 15 (11): 3394-3398
22. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989 Dec 15; 64 (12): 2448-2458
23. Vaughn DJ, Malkowicz SB, Zoltick B, Mick R, Ramchandani P, Holroyde C, Armstead B, Fox K, Wein A. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. Journal of Clinical Oncology 1998; Vol 16: 255-260
24. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000 Sep; 18 (17): 3068-3077
25. Waxman J, Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 1993; 19 (Suppl C): 21-25